SCHEMBL4393170

SCHEMBL4393170

CCCCc1ccc(S(=O)(=O)N2CCC(=NOCc3cccc(OC)c3)CC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PKM P14618 6/20 0.49
LMNA P02545 5/20 0.49
POLB P06746 2/20 0.49
ALDH1A1 P00352 3/20 0.48
GAA P10253 2/20 0.48
HTT P42858 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 2/20 0.45
ALOX15 P16050 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
MAPK1 P28482 1/20 0.43
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 2/20 0.42
FAAH O00519 1/20 0.41
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4376950 0.89 LMNA (0.42) PKMLMNAPOLBALDH1A1GAA
SCHEMBL4385481 0.89 LMNA (0.49) LMNAALDH1A1GAAMEN1KMT2A
SCHEMBL4393905 0.87 SMN1; SMN2 (0.49) PKMLMNAALDH1A1GAAMEN1
SCHEMBL4381771 0.85 LMNA (0.50) LMNAALDH1A1GAAHTTMEN1
SCHEMBL4381221 0.85 LMNA (0.43) LMNAALDH1A1MEN1KMT2ATSHR
SCHEMBL4387319 0.82 ALDH1A1 (0.47) PKMLMNAPOLBALDH1A1GAA
SCHEMBL4377572 0.82 LMNA (0.45) LMNAALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4385837 0.81 LMNA (0.41) LMNAMEN1KMT2ATSHRSMN1; SMN2
SCHEMBL4381821 0.81 LMNA (0.46) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL4385187 0.80 IKBKB (0.42) LMNAMEN1KMT2ATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 PKM 2106/4885LMNA 3822/4885POLB 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.